Mylan
Search results
Viatris is a global pharmaceutical company that produces high quality medicines across a range of therapeutic areas. Learn about its story, products, news, careers and sustainability efforts on its official website.
- Products
Viatris produces high quality medicines across a broad range...
- About Us
Viatris is a unique global healthcare company focused on a...
- Careers
Important Note: Viatris and our recruiting firms will not...
- Newsroom
Viatris Inc. (NASDAQ: VTRS), a global healthcare company,...
- Investors
Viatris is a publicly traded company that is managed and...
- Therapeutic Areas
From cardiovascular health to oncology, Viatris offers...
- Brands
Viatris harnesses the power of numerous branded drugs,...
- Generics
Our generic medicines, which include complex and branded...
- Products
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn , a legacy division of Pfizer , on November 16, 2020.
Viatris is a company that provides access to high quality, trusted medicines across a wide range of therapeutic areas and markets. Learn about its mission, leadership, impact, partnerships, history and contact information.
At Viatris, we provide access at scale. We are a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally.
Viatris brings quality medicines to patients when and where they need them through our Global Healthcare Gateway. Learn about our mission and global impact and reach.
Viatris produces high quality medicines across a broad range of therapeutic areas. Explore our brands, generics, biosimilars, over-the-counter products and API.
Viatris global portfolio comprises more than 1,400 molecules across a broad range of major therapeutic areas, including best-in-class, iconic brand-name products, as well as global key brands, generics, including branded and complex generics, biosimilars and over-the-counter offerings.
